We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Vertex ...

Routines to create rounded corners, with either circular rounding, or continuous curvature rounding with no sudden curvature transitions. Provides rounding of corners or rounding that preserves corner ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Some embittered critics of wokeness have depicted this movement as an in-kind backlash, a “meet the new boss, same as the old ...

One positive sign was that Vertex raised the lower end of its forecast for full-year 2025 revenue by $100 million. The ...

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. However, the big drugmaker had plenty of good news in its Q1 update, too ...

Vertex also picked up a positive Committee for Medicinal Products for Human Use (CHMP) opinion for Alyftrek. As a result, it's looking for European Commission approval for the drug in the second half ...

Vertex shares fell in after-hours trading, as investors considered a stock trading near its all-time high with a longer wait ...

Reserve your free spot now. Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing the consensus of $4.32. The cystic fibrosis-focused company ...

Vertex, Inc. (VERX) kicks off 2025 strong with 12.9% revenue growth, strategic AI investments, and e-invoicing innovations.

The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 13 cents per share. The company posted revenue of $177.1 ...

Why does the brain split visual spatial perception between its hemispheres? A new review by neuroscientists examines the advantages and trade-offs, and how the brain ultimately makes vision feel ...